Equities

Apyx Medical Corp

Apyx Medical Corp

Actions
  • Price (EUR)1.38
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change-48.12%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and OEM. The Advanced Energy segment's product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It is focused on the cosmetic surgery market where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue to achieve their desired results. Its product lines consist of a multifunction generator, a handpiece and a supply of helium gas. The OEM segment leverages its expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers through original equipment manufacturing agreements, as well as start-up companies with the need for its energy-based designs.

  • Revenue in USD (TTM)52.35m
  • Net income in USD-18.71m
  • Incorporated1982
  • Employees252.00
  • Location
    Apyx Medical Corp5115 Ulmerton RdCLEARWATER 33760-4004United StatesUSA
  • Phone+1 (727) 384-2323
  • Fax+1 (631) 421-5821
  • Websitehttps://apyxmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.